|
|
8/22/2005 12:56:28 PM ET
SWISS MEDICA REPORTS STRONG INITIAL SALES OF NEW O24 FIBROMYALGIA™ AT PROHEALTH.COM
FOR IMMEDIATE RELEASE
Stock Symbol: OTC BB: SWME
Aug 22, 2005
SWISS MEDICA REPORTS STRONG INITIAL SALES OF NEW O24 FIBROMYALGIA™ AT PROHEALTH.COM
TORONTO--(BUSINESS WIRE)--Aug. 22, 2005--Swiss Medica, Inc. (OTCBB: SWME) today announced that its
recently-launched O24 Fibromyalgia™ pain reliever is enjoying strong sales through the ProHealth medical
channel distribution. In early August, ProHealth began offering O24 Fibromyalgia™ to its customers through its
online website, www.prohealth.com – and within days, the product shot straight to the number 3 spot in terms of
volumes of product sold through prohealth.com.
“We have received very positive feedback from both our Fibromyalgia and general pain audiences regarding
O24 Fibromyalgia™” says ProHealth President Dennis Schoen. “The product has earned a 4.5 on 1-5 point
scale, with 5 being the most efficacious. Customer comments range from benefits for Fibromyalgia symptoms as
well as for helping patients dealing with other non-related pain issues.”
ProHealth, Inc. the publisher of the largest Fibromyalgia and Chronic Fatigue Syndrome web site, Immune
Support.com introduced Swiss Medica's O24 Fibromyalgia™ product on August 8, 2005. ProHealth's multi-
pronged launch of this product, formulated to improve the lives of Fibromyalgia patients, included an emailing to
its subscribers and prominent inclusion on Immune Support, where eight million people visited last year for the
latest news on Fibromyalgia and Chronic Fatigue Syndrome research, interviews, treatment options and support.
Additionally, ProHealth is actively supporting distribution through its network of 5,000 physicians.
The early success of the product has also been warmly received by the National Fibromyalgia Association (NFA).
In June, O24 Fibromyalgia™ became the first product to carry the NFA’s new official Seal of Approval.
O24 Fibromyalgia™ is the first product of its kind developed to specifically address the symptoms of long term
pain associated with fibromyalgia syndrome and is a patented and clinically tested, strong and safe, all-natural,
over-the-counter health product. Swiss Medica is the owner, maker and distributor of this product. Swiss Medica
president, Grant Johnson said that he is highly encouraged by the resoundingly positive response from
consumers using the ProHealth.com website. O24 Fibromyalgia™ will be available in national pharmacies in the
United States in the fall of 2005.
“This is a real validation about the demand we see for this product – and it is great to see such strong initial
interest from the health care professionals who use ProHealth,” he said. “We have known for some time that
Fibromyalgia sufferers were crying out for a natural, non-prescription, safe product that could them with pain
relief – and we are very happy that we were able to develop it and bring it to market.”
Fibromyalgia is typically characterized by widespread musculoskeletal aches, pain and stiffness, soft tissue
tenderness, general fatigue and sleep disturbances. The most common sites of pain include the neck, back,
shoulders, pelvic girdle and hands. Fibromyalgia patients experience a range of symptoms, varying in intensity
that can fluctuate over time. The NFA estimates that the average family doctor sees at least one patient each
day who is suffering from fibromyalgia and that the syndrome could cost U.S. economy as much as $10 billion a
year in lost productivity.
About Swiss Medica, Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a
world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com
Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by
healthcare professionals and athletes in the United States, Canada and in Europe. O24™ is widely available
throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit
www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS
Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce
changes in mood and appetite that women experience during the premenstrual period. Customers can also visit:
www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United
States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
transactions being contemplated, risks related to international sales and potential foreign currency exchange
fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
periodic reports filed with the United States Securities and Exchange Commission and other regulatory
authorities.
For more information, please contact:
Swiss Medica Inc.
Investor Relations Contact:
David Jones
(866) 485-4243
djones@swissmedica.com
|
|
